AMY ROMICK: Open Payments
NPI 1447771290 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,707 in 134 payments from 13 companies in 2025. Trend: 2023 $166 · 2024 $1,621 · 2025 $2,707
Food & beverage: $2,707
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $697 |
| Otsuka America Pharmaceutical, Inc. | 42 | $668 |
| Alkermes, Inc. | 14 | $266 |
| Neurocrine BioSciences, Inc. | 13 | $253 |
| Teva Pharmaceuticals USA, Inc. | 9 | $157 |
| Lundbeck LLC | 9 | $140 |
| Vanda Pharmaceuticals Inc. | 9 | $140 |
| ACADIA Pharmaceuticals Inc | 5 | $121 |
| Genentech USA, Inc. | 5 | $117 |
| E.R. Squibb & Sons, L.L.C. | 3 | $78 |
Products named: CAPLYTA, REXULTI, ARISTADA, INGREZZA, AUSTEDO XR, VYEPTI, NUPLAZID, Ocrevus Zunovo.
Industry payments across TX — which companies pay providers there.
